Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes
MD Gans, T Gavrilova - Paediatric respiratory reviews, 2020 - Elsevier
Asthma is a common disease in paediatrics and adults with a significant morbidity, mortality,
and financial burden worldwide. Asthma is now recognized as a heterogeneous disease …
and financial burden worldwide. Asthma is now recognized as a heterogeneous disease …
Roles of IL-25 in type 2 inflammation and autoimmune pathogenesis
C Deng, N Peng, Y Tang, N Yu, C Wang, X Cai… - Frontiers in …, 2021 - frontiersin.org
Interleukin-17E (IL-25) is a member of the IL-17 cytokine family that includes IL-17A to IL-
17F. IL-17 family cytokines play a key role in host defense responses and inflammatory …
17F. IL-17 family cytokines play a key role in host defense responses and inflammatory …
Monoclonal antibodies targeting alarmins: a new perspective for biological therapies of severe asthma
Alarmins are innate cytokines, including thymic stromal lymphopoietin (TSLP), interleukin-33
(IL-33), and interleukin-25 (IL-25), which are mainly produced by airway epithelium and …
(IL-33), and interleukin-25 (IL-25), which are mainly produced by airway epithelium and …
Emerging biological treatments for asthma
D Pastore, C Lupia, M D'Amato, A Bruni… - Expert Opinion on …, 2025 - Taylor & Francis
ABSTRACT INTRODUCTION Severe asthma is a chronic airway disease characterized by
many pathomechanisms known as endotypes. Biological therapies targeting severe asthma …
many pathomechanisms known as endotypes. Biological therapies targeting severe asthma …
[HTML][HTML] Biologics in asthma management–Are we out of breath yet?
N Struß, JM Hohlfeld - Allergologie Select, 2021 - ncbi.nlm.nih.gov
The biologics authorized for the add-on therapy of severe asthma are monoclonal
antibodies (mAbs). Before they are considered for therapy intensification, the patient's …
antibodies (mAbs). Before they are considered for therapy intensification, the patient's …
Biologika in der Asthmatherapie–ist hier noch Luft nach oben?
N Struß, JM Hohlfeld - Allergologie, 2021 - search.proquest.com
Die Biologika, die für die Add-on-Therapie des schweren Asthmas zugelassen sind,
gehören zu den monoklonalen Antikörpern. Bevor sie für eine Therapieintensivierung in …
gehören zu den monoklonalen Antikörpern. Bevor sie für eine Therapieintensivierung in …